Revvity (NYSE:RVTY) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Revvity (NYSE:RVTY) released its earnings results on Monday. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.06, Zacks reports. Revvity had a return on equity of 7.68% and a net margin of 9.81%. Revvity updated its FY 2025 guidance to 4.900-5.000 EPS.

Revvity Stock Performance

NYSE RVTY opened at $94.30 on Monday. The firm’s 50 day simple moving average is $104.87 and its 200 day simple moving average is $112.98. The firm has a market capitalization of $11.33 billion, a price-to-earnings ratio of 42.67, a P/E/G ratio of 3.82 and a beta of 1.07. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. Revvity has a 1 year low of $88.53 and a 1 year high of $129.50.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity’s payout ratio is presently 12.67%.

Insider Activity

In other news, insider Joel S. Goldberg sold 15,170 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the sale, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.68% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Raymond James restated an “outperform” rating and set a $145.00 target price (up from $140.00) on shares of Revvity in a report on Monday, February 3rd. Robert W. Baird dropped their target price on shares of Revvity from $141.00 to $127.00 and set an “outperform” rating on the stock in a report on Monday, April 21st. KeyCorp lifted their price target on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Wells Fargo & Company lowered their price target on Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Finally, Sanford C. Bernstein cut Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective for the company. in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $130.50.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.